Related Experiment Video
Updated: Feb 16, 2026
A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
Targeting the CXCR4/CXCL12 axis with the peptide antagonist E5 to inhibit breast tumor progression
Hua Guo1, Yangyang Ge1, Xiaojin Li1
1Department of Biomedical Engineering, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China.
Abstract:
Emerging evidence has demonstrated that stromal cell-derived factor 1 (SDF-1) and its cognate receptor CXCR4 have critical roles in tumorigenesis, angiogenesis and metastasis. In this study, we demonstrated the significant inhibitory effects of a novel chemically synthetic peptide (E5) on the CXCR4/CXCL12 axis in breast cancer both in vitro and in vivo. E5 was capable of specifically binding to the murine breast cancer cell line 4T1, remarkably inhibiting CXCL12- or stromal cell (MS-5)-induced migration, and adhesion and sensitizing 4T1 cells to multiple chemotherapeutic drugs. Furthermore, E5 combined with either paclitaxel or cyclophosphamide significantly inhibited tumor growth in a breast cancer model. Mechanistic studies implied that E5 can inhibit the expression of CXCR4 to block the CXCL12-mediated recruitment of endothelial progenitor cells and repress CXCR4 downstream of the Akt and Erk signaling pathway, which are involved in tumor angiogenesis and progression. Further pharmacokinetic evaluation suggested that E5 has an acceptable stability, with a half-life of 10 h in healthy mice. In conclusion, E5 demonstrates a promising anti-tumor effect and could be a potential chemotherapeutic sensitizer to improve current clinical breast cancer therapies.
Insights
A novel peptide, E5, effectively inhibits breast cancer growth and metastasis by targeting the CXCR4/CXCL12 pathway. E5 also enhances chemotherapy efficacy, showing promise for improved breast cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Stromal cell-derived factor 1 (SDF-1) and its receptor CXCR4 are implicated in breast cancer progression, including tumor growth, angiogenesis, and metastasis.
- Targeting the CXCR4/CXCL12 axis presents a potential therapeutic strategy for breast cancer.
Purpose of the Study:
- To investigate the anti-tumor effects of a novel synthetic peptide, E5, on the CXCR4/CXCL12 axis in breast cancer.
- To evaluate E5's efficacy as a sensitizer for conventional chemotherapeutic agents.
Main Methods:
- In vitro studies using the 4T1 murine breast cancer cell line to assess E5's effects on cell migration, adhesion, and chemosensitivity.
- In vivo studies in a murine breast cancer model to evaluate tumor growth inhibition by E5 alone and in combination with paclitaxel or cyclophosphamide.
- Mechanistic investigations into E5's impact on CXCR4 expression, endothelial progenitor cell recruitment, and downstream Akt/Erk signaling pathways.
- Pharmacokinetic evaluation of E5 stability and half-life in healthy mice.
Main Results:
- E5 specifically bound to 4T1 cells and inhibited CXCL12-induced migration and adhesion.
- E5 sensitized 4T1 cells to multiple chemotherapeutic drugs.
- Combination therapy with E5 and paclitaxel or cyclophosphamide significantly inhibited tumor growth in vivo.
- E5 was found to inhibit CXCR4 expression, block endothelial progenitor cell recruitment, and repress Akt/Erk signaling.
- E5 exhibited acceptable stability with a half-life of 10 hours in mice.
Conclusions:
- The novel peptide E5 demonstrates significant anti-tumor activity against breast cancer by targeting the CXCR4/CXCL12 axis.
- E5 acts as a potent chemotherapeutic sensitizer, suggesting its potential to enhance current breast cancer therapies.
- E5 warrants further investigation as a promising therapeutic agent for clinical application in breast cancer treatment.
More Related Videos
06:56A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4
Published on: March 10, 2018
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Related Concept Videos
02:38Mitogens and the Cell Cycle
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...